# Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

> **NCT00971763** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 62 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** prednisolone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00971763
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2014-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00971763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00971763, "Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00971763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*